Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Devyser Diagnostics, Capital Markets Day, 2024

By Inderes11/25/2024, 12:30 PM
Devyser Diagnostics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik
00:05 - 11:08

Welcome to the 2024 Capital Market Day. It's a real pleasure to see you all here. It's actually the first time we have a Capital Market Day like this. I'm really glad to see so many participants, actually more than we expected. So I apologize for it being a bit crowded. I'm also glad that we can be here in our new facility, and after the meeting, you will have a chance. If you haven't seen it yet, take a tour around the facility. The day today is also being taped. I know that quite a few will watch afterward. We have seen exceptional increased interest in devices over the last year, and I think this capital market day is a good opportunity for you to learn more about the company, but also to ask questions and get them answered. Today's speakers, in addition to myself, include our Chief Scientific Officer, Doctor Michael Ulin, and our Chief Commercial Officer, Tyson Kipling. Our US-based Vice President. Our Vice President, Market Access and Reimbursement, will also speak today. And his name is Jeff Saltzman. You will also listen to Jakob Nielsen, who will speak a bit later after the break. They will all introduce themselves in connection with their presentations. In the audience, we also have our CFO, Sabina Berlin, to my right here, and Camilla Weber, also to my right. At the end of the room, we have one of the founders and our head of Italy, Virginia O'Mara. We also have the tall guy over there. It's Ole, his Vice President of Quality and Regulatory Affairs. Don't hesitate to reach out to them during the break or afterward. If you have a question that you would like answered. We also have three board members here: our chairman, Mia Arnold, Thomas Ecklund, and Laura Hagerstrom. Today's agenda: I will start with a recap of the Weiser. Michael will then give an overview of our product portfolio. Our Chief Commercial Officer, Tyson Kipling, will walk us through our commercialization strategy plan. Our Vice President, Market Access and Public Affairs, Jeff Saltzman. He will speak about our work in the US when it comes to market access and reimbursement. And his presentation has been taped to avoid interruptions. But he will be online during the Q&A session 20 to 3. We have a break, a 20-minute break, and we will serve coffee in the lounge where we met just before the meeting. After the break, we will listen to Doctor Jakob Nielsen from the University of Zurich. He will discuss the opportunities he sees with cell-free DNA. After that, I will give some closing remarks. We will have a Q&A session at the end of the day, but it's also okay to ask questions directly after each presentation. We may save them until the end for the general Q&A session. For those who are interested, we will have a guided tour of the facility just after the meeting at 4:10. You should then be in the reception area where you came in. Advisor. We are driven by a passion among the employees to help patients get the correct diagnosis in the shortest possible time because we know that helps people to live longer, and we save lives with this. Both my colleagues and I. So even if high revenue growth and high margins are important for us, that's not the reason why we go to work every day. We know that our work can help people live longer. Our mission is to be the pioneering leader in diagnostic solutions and provide fast, accurate, and easy-to-use solutions to labs worldwide. Our vision is a world where personalized medicine is universally available thanks to simplified and reliable genetic tests. Device is a pioneer in utilizing next-generation sequencing technology. NGS technology enables highly accurate and sensitive testing and has thereby transformed precision medicine. The advancements in technology have made early detection and early intervention more accessible to more patients. It has significantly improved patient care and reduced healthcare costs. However, we strongly believe that we are just at the beginning of a fantastic future journey. So what's the reason for our success? Our customers select our devices because we provide simple, accurate, and efficient genetic testing solutions. Our kits and software are easy to implement, maintain, and use. This simplified workflow has been the foundation for our successful growth. Because we design our products with a deep understanding of the clinical laboratory workflow and put the genetic laboratory team in focus. We sell solutions that are streamlined to fit the lab's workflow, thereby saving time and, by saving time, saving money. Thus, there are financial incentives for our customers for the labs to use our products. It may differ slightly between different competitive products, but in general, for our products compared with competitive products, a lower amount of DNA is needed and less pre-processing is required. We reduce the hands-on time. We also reduce the total time for the laboratory. The training time for lab staff is significantly shorter with our products than with competitive products. The company is celebrating 20 years this year. Many things have happened since the company was founded in 2004. The list can be very, very long. If I were to pick a couple of them, the most important milestones I would pick are the regulatory approvals in Europe, including the IPR approvals as early as 2022. I would also pick the switch from distributor sales to direct sales in certain countries. Other important milestones are the signed agreements with the industry giants Thermo Fisher and Illumina during 2023 and 2024. A final pick would also be our decision to set up our own CLIA-certified laboratory in the US last year. I'm sure we can look back on these milestones and see them as fundamental cornerstones in our success. We sell genetic testing solutions to guide targeted cancer therapies, diagnose hereditary diseases, and provide products for post-transplantation monitoring. All development and all manufacturing are taking place in-house here in this facility in Stockholm. But we also have almost ten subsidiaries abroad, with sales offices in total. We currently have approximately 120 employees. We offer products within three areas. The biggest is hereditary diseases. It represents about 70% of our total revenue. The second biggest is oncology tests; they represent. They represent about 20% of our total revenue and the smallest. But how about the area with the highest growth? It's our transplantation products, and they represent over 10% at the moment. The growth in the company is high. It has been that, and it still is. And I would say it's actually very high. Since 2015, we have had a CAGR of 35%, and we reached 200 million SEK in revenue for the last 12 months. With our innovative products, high market growth, and a well-suited commercial organization, we do not see anything at the moment that can prevent us from having the same successful development. Also, going forward, it should be pointed out that we have only invested in building up a commercial organization in the last few years. Implementing a commercial organization and entering into commercial agreements with industry giants will help us drive sales in the future. With this short introduction, I would like to hand over to our Chief Scientific Officer, Mikael Olin, and he will give an overview of our product portfolio.

Mikael Olin
11:13 - 26:49

Thank you, Fredrik. So I will now quickly walk you through our product portfolio. And then I will spend some time on our future focus areas. And then I will even glimpse and show you a little bit about the hints of the future for devices. I joined Weiser last year. Responsibility for research and development, innovation, clinical affairs, and also the laboratory activities over in the US. I still have my professorship at Karolinska in Clinical Immunology, which is very nice to have both parts. I used to be the head of the Clinical Immunology department at Karolinska University Hospital, and I held several leadership positions in academia, university, hospital, and industry. I started my career in infection biology when I did my PhD, and then I shifted into a more translational environment. So, an environment very close between the clinic and the bench. So, where did you do lab work? So I shifted into immunology and I also worked extensively in transplantation. So even if I only joined the Weiser last year, I have actually dealt with devices for more than five years. I dealt with devices as a clinical customer using some of their products for more than five years. And this was a very good experience. I mean, very good, very solid products. So when I had the possibility to join Weiser last year, I also was fortunate because over the years several people have moved from the hospital environment to Weiser. So I had a lot of informal former colleagues that I could call, and then I could ask them, should I join the visor? And I got a very uniform answer from all of them saying, yes, please. Because this is an environment of very high dedication. There's a lot of knowledge in the house, and also we are commonly in the Weiser striving for providing as good and accurate precision medicine in the form of diagnostics for our patients. And I would say that honestly, that was a big factor in making the transition to the Weiser last year, which I definitely do not regret. So if you look at the Weiser, it stands on a very solid foundation. It has over 25 well-established diagnostic kits on the market, and we are definitely a respected name in hereditary diseases, oncology, and transplantation, as Frederick mentioned since a couple of years. And what is also nice is that it definitely shows our focus on quality over the years. While we have exceptionally low customer complaint levels on our products. Two decades of work. I mean, it's the 20th anniversary for the Weiser this year. Hard work, craftsmanship, and perfectionism have definitely solidified our reputation for continued growth into the future. Another very good thing with the visor is that historically, the devices have been constantly at the forefront of technological advancements, adopting early different breakthroughs in molecular biology. So we are in PCR, we have our legacy products and fragment analysis. And we also have very successful kits in next generation sequencing. But of course, to be this wide, there are also, you could say, both opportunities. But we have to prioritize. We have to prioritize so we can maintain excellence in the fields that we are operating. So while fragment analysis continues to have steady growth, we have actively chosen to shift more resources to developing products in the area of next-generation sequencing. That's not to say that we will forget the fragment analysis. We will still do regulatory upgrades if necessary, but more focus is put on the newer technologies, and this decision will definitely make us more competitive and aligned with future developments of technological platforms. I have a very nice task now, and that is that I will give you some highlights for 2025. I must say that it's not an easy task because there are so many activities ongoing, but I have picked what I think is most interesting and I will share three different categories with you. I will share three new products launched in 2025, some improved software highlights, and also some enhanced regulatory compliance. So we can start with the regulatory upgrades. So during 2025, we will aim to secure IPR status on two of our blockbuster products: CFTR. So cystic fibrosis and also thalassemia. Thalassemia will also add some additional features based on feedback we have received from clinical customers. So it will make the product even more competitive against other companies. Nowadays, it's important that we deliver not only chemistry but the entire solutions involving the software, because the software is as important as the chemistry in order to provide accurate results to the clinicians and later the patient care. So during next year, we will provide an AI-based tool to complement our existing products with regards to organ transplantation. We have a new software suite for transfusion medicine products, and we will further secure IPR status on our transplantation software. The three new products, with the working names Genomic Blood Group Typing, Fetal Typing, and HLA Loss, will be discussed in the upcoming slides. So genomic blood group typing. So this involves typing to make the matching as accurate as possible between donors or blood products and recipient patients. So very quickly, I will define transfusion medicine for you. So transfusion medicine is a branch of medicine which is concerned with everything from collecting blood from donors, to testing, processing, and storing. And then in the end line, transfusing these blood products into the patient that is in need. And often, these are patients that are severely ill after major trauma, big surgeries, or other very critical complications. So the field of transfusion medicine is a very conservative area. They have, more or less, I'm not exaggerating. Using the same techniques for decades with regards to matching donor recipients, but now they are on the brink of making a big introduction of molecular technology. And that is next-generation sequencing. And this, to a large degree, resembles the situation of transplant diagnostics 15 to 20 years ago, when they made a shift to more advanced molecular technology, and at that time, the advisor was present. The visor could introduce chimeras and it could later introduce the accept kit. And we are now there and seeing this happen, and Visor wants to assist in making this transition in the transfusion medicine category as well. So how will we do that? We already have potential products that will complement the RHD product that we have. We are running several ongoing clinical studies already, and that is very beneficial. As we come back to the next slide, we will already have clinical data when the product is out on the market to show that it has clinical validation and utility. And we are building our own software in order to interpret the results from the kits. The second product's working name is Fetal Typing. The clinical situation here is that if there are certain proteins differing between the mother and the fetus, there is a risk that the maternal immune system will create a response against the proteins in the fetus. In this response, fortunately, it's not such a big problem during the first pregnancy and the baby is born, but unfortunately, the response in the immune system will remain as a memory for the second pregnancy. And then you might have, in certain cases, a lethal immune reaction against the fetus, which will have lethal consequences for the baby. So we have now developed a comprehensive NGS-based kit and corresponding software that can predict. This can be used early during pregnancy, is non-invasive, and is a very good complement to the original kit, either as a reflex or as a complementary measure. And we have also the same situation with this one as mentioned in the previous slide. We have a clinical study that has already been finalized, showing that the clinical utility for this is highly beneficial. And thirdly, there's the HLA loss. I'm not saying it's worth more or less than the other two products; maybe it's a little bit closer to my heart since it's related to transplantation, which ties back to my background. The situation here is that tumor cells, unfortunately, are quite smart. I mean, they want to grow. They want to grow as much as possible in whatever situation they are in the body. And unfortunately, they are going to create problems and disasters. And in order to do that, one of the things that the tumor cells have to do is escape the immune system, because one of the main actions of the immune system is to strike down and kill tumor cells. And it has several mechanisms to do this. Avoid all stem cell transplantations. There is a particular mode of action for the tumor cells, and that is to literally expel parts of a chromosome. And the chromosome it expels has the information needed to create the proteins that are crucial for the immune system to recognize the tumors. So what the tumor does in this situation is that it becomes invisible to the immune system. And of course, that's not really good. And then it will come back in the form of a relapsing malignancy. And this information, if this happens, is very important for the clinicians, because if they know that this has happened, it will directly influence which kind of treatment modality they will use in order to save the patient. If they don't have the information, they might even end up using a treatment modality that will be directly lethal. And this, of course, will be a very good complement to the chimerism assay of the stem cell transplantation. So this is a very neat. An innovative step utilized by our very dedicated crew in the visor. It's important also not to bring down the value of these things. But it's also important not only to work on short-term advancements with new products, you also have to work a little bit more on the long-term, and that could be long-term innovation by developing the technical platforms that we are using in order to produce the products. And I'm very happy to say that at the moment, I think that within the visor, we have made a leap in the sense of upgrading the technical platform by adding absolute quantification of cell-free DNA. I will not say more than what that means. I know that Jakob Nielsen in the last lecture is going to mention a little bit more about cell-free DNA, but you have to take my word that I see it as a leap. If it's a big leap or a small leap, we will see in the coming years. But it's important to have both the long-term and short-term focus. So this particular innovation, with regards to the technique, I see as a potential upgrade of the device or engine with regards to the technical platform, and that is something then that will provide us with a very interesting and potential choice. Where should we put this engine? Should we integrate this into the transplantation area? I would guess yes, somehow, because that is where the invention comes from, but it also opens up other possibilities. Maybe we can also explore inflammatory diseases and companion diagnostics. It can also potentially be used as a liquid biopsy marker. Looking at oncology minimal residual disease. Sports medicine. There are a lot of opportunities here and we will see where we go. But it's definitely very promising. Before ending and leaving the word to Tase, I also want to mention our extensive clinical study program, something that is very important. We are actively initiating and sponsoring clinical studies. By doing that, we gain entry to different hospitals. And we also create future customers because once they have used our excellent products, they become committed and continue using them. We are actively involved in more than 30 clinical studies across five continents. It ranges from scientific studies where we work together with clinics in order to test our new concepts. Regulatory studies where we need information for IVR or potentially FDA multicenter studies, and also small studies. For validation studies, when one clinic is interested in implementing something, we provide them with a couple of kits. We interact with them. We provide them with some guidance on how they should conduct the studies. And then when they like it, they start using them. And here you see some logos of the many centers that we collaborate with. And now, of course, being a little bit picky, we pick the best ones. But several of these, like Mayo Clinic, UCL, and University Hospital Zurich, are among the top ten university hospitals in the world. And together with all of these names. Yeah, now you have a devices brand, which I think is very, very nice. Hand in hand with this, we are also getting more scientific traction. This is also important because you have to remember that many of these clinicians, who are stakeholders deciding if they are going to go for our products, are also scientists. So, they are going to read scientific papers, and then those papers are going to be part of the decision-making process on whether they will use our device products in the end. By making a simple search, there are more than 30 scientific papers from just the last couple of years. And that's a massive increase compared to earlier years. And that's mainly NGS products, actually nine different products in scientific papers and also scientific congresses. I'm happy to say that Jakob Nielsen, who is here to present, is one of the members of our scientific board. And here you have some examples of publications where we either work very closely together with centers, or we review the scientific papers afterwards, because people have used our product and they want the rest of the scientific community to present the data that they have achieved. So I end with saying that I think that the future looks not bright, but super bright. And then I hand it over to you.

Fredrik
26:49 - 26:58

If we're doing that, maybe we have some questions for Michael. And please raise your hand and you will get the microphone.

Unknown 1
26:59 - 27:01

Great. Is it on?

Ulrich Trattner
27:03 - 27:48

Now? Hello? Yeah. Great. Thank you very much. Attractive from Carnegie. Um, a few questions on my end. And, Frederick, I promise you, I will keep it to a maximum of two. Perhaps start off with the larger, fundamental question: the most important thing about Divisor is its platform, the development engine, the one-tube solution. And I think one crucial aspect here is how tricky it is to copy this concept. Like, you obviously have been doing this for quite some time, a few decades, and nobody has copied it. But it is part trade secret, part patented. So if you can give us some type of clarification on how well-protected your moat is.

Mikael Olin
27:49 - 28:21

So the patents are still valid for sure. I would say I would speculate a little bit that it's not so easy to just copy it straight out, because many competitors have gone a long way in another direction, not aiming for a one-tube solution, and then suddenly introducing that into an already established workflow. That's not easy. So I would say that that also strengthens what you say, not by patents, but by the traits of the advisor. It will take many years for other competitors to go in that direction from where they are at the moment.

Ulrich Trattner
28:23 - 28:29

I would have a follow-up question, but since I only have, I only have two. No, you have one.

Fredrik
28:29 - 28:29

More.

Ulrich Trattner
28:31 - 28:55

I will take that one to the end. But another aspect, the software part. You talk about quite a lot of software upgrades, and if I'm correct, software has been kind of a soft spot within devices in comparison to competitors. So where does your new software stack up against your main competitors out there? Your SOPHiA GENETICS, your RDX? Et cetera. Et cetera.

Mikael Olin
28:56 - 29:00

And now you're talking about the ones I mentioned for transfusion medicine or in general.

Ulrich Trattner
29:00 - 29:05

In general, sort of where we're coming from and where we are at today in terms of the new software development.

Mikael Olin
29:06 - 29:24

Okay, so I will not admit that we have a soft spot. I think it has been developed quite a lot during recent years to increase the standard of it, but it can definitely be improved further. But I think that we have two very good teams, so I believe we are definitely competitive regarding software.

Ulrich Trattner
29:25 - 29:25

Thank you.

Fredrik
29:26 - 29:29

I think we have time for one or two more questions.

Unknown 1
29:34 - 30:04

So the patents are still valid for sure. Um, yeah, perhaps just to. So, first of all, you talked about these new tests planned for 2025. So the plan is to launch them in 2025. Yeah. So the patents are still valid for sure. And then the follow-up is regarding this HLA test. So that is a tight connection to the Chimerism test, and you now have a deal with Thermo Fisher. So, are you planning to include that into the agreement as well? Or are you going to try to sell it by yourself?

Mikael Olin
30:04 - 30:06

That question I leave to Chase.

Thijs Kipling
30:06 - 30:17

I think that, um, we have not yet provided guidance on this, but I believe there's logic in what you're saying; however, we are yet to confirm. Okay.

Unknown 1
30:18 - 30:20

Okay. I'll stop there. So, are you planning to include that into the agreement as well?

Fredrik
30:22 - 30:35

Ludwig, did you have a question? No. No. Okay. Thank you. Michael. There will be more time for further questions at the end. So please, guys.

Thijs Kipling
30:36 - 47:07

So, are you planning to include that in the agreement as well? And thank you, Michael also. I mean, making leaps is why we are here, and especially representing the commercial organization as you will surely appreciate. You'll see also that we will be sharing these deep dives at this Capital Markets Day, as well as future Capital Markets Days, so you will get a deeper dive at these events more than you will see at the earnings calls. For the sake of introduction and for those I have not personally met yet, my name is Thijs Kipling and I have been the Chief Commercial Officer since 2022, when I joined Divisor from a similar position at a Stockholm-based company called Atlas Antibodies, a subsidiary of Patricia Industries. I'm Danish, as you may hear from my accent, and I'm living north of Copenhagen with my family, two kids and my wife. But I worked here on site in Stockholm for the past four years. And I've been working throughout my career in international positions within the healthcare industry. My dark past is that I'm initially from the numbers side of things, as I have a master's degree from Copenhagen Business School in finance and a background. An initial part of my career was within controlling. Let's dive into the divisor part. So at Divisor, as you have heard, we are serving three verticals across oncology, hereditary disease, and transplantation, which represent a very, very large addressable market of several billions of euros. Oncology is by far the most competitive, and transplantation is the area where we have the most growth. Due to the size of the available market, we will have a very large market to collect revenues from in the many years ahead of us. When looking at a Q3 year-to-date level on revenues, the split is 21% of the revenue sitting within oncology, another 67% sitting in hereditary, and 13% sitting in transplantation. From a new launch perspective, we have, as you heard from Michael, one new product in 2025. Within oncology, we have 2 to 3 products in the hereditary category. And we have 4 to 5 within transplantation to be launched. Hence, we expect to be able to maintain growth across these verticals. Or potentially even exceed that growth across these three verticals. However, transplantation continues to be the fastest growing portfolio. It's worth noting down here to the bottom right, the increased number of indications within solid organ transplantation for post-transplantation monitoring, which we in particular are very excited about. And you'll hear a lot more about that in the remaining slides here. You've heard me say before that we are commercializing through four distinct channels. The first being direct sales, which we use for established markets and it is our preferred channel when markets are large enough to host our own sales force. The second channel is partners, where we currently have Thermo Fisher. Partnerships can be either exclusive or non-exclusive, and usually, partners take a larger responsibility for regulatory issues, for customer support, and the liaison towards key opinion leaders. The third channel is lab services. A recent investment of ours is our CLIA-certified laboratory in Atlanta, Georgia, in the US, where we are currently selling services using both our own products and running services on behalf of third-party companies, such as the UK-based oncology company named Cited. As well as there will be pharmaceutical companies. The fourth and last channel is distributors, which can be exclusive as well as non-exclusive, and where we today have around 50 distributors globally. Now we will move into the transplantation part of the portfolio, which is the fastest growing. As I've mentioned, I will be focusing my presentation on the transplantation business here and especially focusing it on the US opportunities that we are seeing, with particular focus on the FDA program that we have announced for our solid organ transplantation test. There are several reasons why we decided to pursue this investment for FDA clearance, but the main reason is that we believe in democratizing testing into local hospitals instead of the big corporate testing service companies that dominate this field today. Divisor has, since day one, developed our tests with the mindset of these being simple enough to work in any local laboratory. Simple and local will lower costs for laboratories while increasing patient benefits through a faster turnaround time. Currently, the reimbursement for solid organ testing as a service is around 2,800 USD, or equivalent to approximately 30,000 Swedish kroners. Today, there is no FDA-cleared test for monitoring of solid organs. And consequently, there is no reimbursement. Aside from some general codes which may or may not be recognized for reimbursement. And you'll hear Jeff talk about this later on. Our main competitors' tests, they have all been developed as send-out tests, which makes it difficult and usually tedious to implement into a local laboratory. Whereas when it comes to our tests, it's exactly the opposite. In addition to this, we have also conducted extensive market research in the US, informing us that customers actually want to bring this testing back home, localizing it in their own laboratories. Hence, we see several reasons making us believe that we can actually carve out a fairly attractive market share within this field in the US. In our view, an FDA approved test for solid organs can change the revenue flow in the market, which will then drastically alter the landscape in the market. That would in turn improve the turnaround time, which is going to be critical for patients, as well as lower the general costs for society on a per test basis. The picture to the left shows the current flow in the market, with the hospitals sending their samples to the services laboratory, which is then running the tests, sending back the results, and collecting the reimbursement from the payers. In the picture to the right, we try to show how we believe that the revenue flow within this market will change following an FDA approval. In this situation, a hospital can run the tests themselves and, in a much shorter time, provide an answer to the patient, and then collect the reimbursement from the payers. This, we believe based on the market intelligence and research, will make patients and hospitals want to take back the testing as it both benefits their patients, as mentioned, and not least benefits hospitals through this new revenue stream. So we maintain our belief that the services business will also remain large and attractive. So there will be two markets to serve. And hence, we do anticipate that our lab will increasingly capture market share within that specific channel. Moving into how the future could look like. So to provide some models on what success might look like. We have shown revenue potential in a scenario with a 2% market share versus another scenario with a 25% market share. The way of monitoring is different with newly transplanted patients in their first 1 or 2 years following transplantation versus the maintenance patient group who are already living with a transplanted organ. The main difference is in how frequently you're being monitored, in addition to the number of times that a patient is monitored, which can vary across organs, usually with the heart being the indication where the most frequent monitoring happens. And there we have one of the experts in the room who can provide more insights into this specific element, including how far monitoring has progressed as a concept within the market? The potential revenues might range from about half a billion in the 2% scenario to up to 6 billion in the 25% scenario. On the total population perspective within the US alone. What is difficult to assess at this point is the proportion of the market staying within services. Regarding the left side, it's about assessing the market share we can capture with the shift towards the right side in the previous picture. The scenario of the FDA approved assay here is important to note that we estimate that the manufacturer of the test would keep one third. That's going to be important. Usually in the US, the manufacturer keeps one third of a localized test and reimbursement. As we are planning to commercialize together with Thermo Fisher, there will also be a revenue sharing with them. But despite all revenue sharing across hospitals and channels, there is still a potential revenue stream to derive of approximately up to 1 billion Swedish kronor, which is a lot more than what we are dealing with today. Part of our belief in reaching, or even potentially exceeding 25% comes from the partnership with Thermo Fisher, leveraging their dominant market position within the transplantation space. During the next two slides, I will be providing you with another level of detail and insights on the other parts of the business and beyond what we usually share, as already mentioned. When we look at verticals and technology, both are performing really well and are gaining market share as they share the compound annual growth rate (CAGR). Here, I have used a three-year horizon and extrapolated our 2024 Q3 year-to-date numbers by dividing them by three and multiplying by four to get a full-year number for 2024. That said, we see a strong 28% CAGR in both oncology and hereditary, while the transplantation vertical grows 73%. But that's just accounting for up until Q4. And as you've heard Fredrik share at the earnings call, we received a large order from Thermo Fisher in October, meaning in Q4, which is not included in this number. Moving to the technology side and from a technology perspective, our oldest portfolio, the fragment analysis portfolio, continues to take market share by growing impressively 14% in a market that grows in modest single digits. Our NGS portfolio grows 34%. But again, you need to note that this is without the order I just mentioned, which we got from Thermo Fisher for NGS products in October. Lastly, the PCR portfolio, representing our RTD test, has grown by 43%. And here, for those who follow the press releases, you will note that we have declared winning a major tender in Wales. We have great traction in Canada and expect to see traction in the US soon, which is not yet reflected in the numbers. When taking a look at our individual high-performance products aside from transplantation and RHD, we see our tests for cystic fibrosis growing 27% and thalassemia growing 53%. Both of these products have a lot of potential and will continue to grow fast, not least in the US. On a final note, it's also worth mentioning that we have been able to increase prices by 9% in 2023. Another 8% in 2024. And we have just flagged an average 7% increase for 2025, something that we have carefully decided on following price analysis, market and competitor analysis. And obviously combining that with our own price-to-value assessment. So with that, I am closing the commercial deep dive, handing it over to Jeff Saltzman in a pre-recorded video. But Jeff, as communicated, will be with us live for the Q&A session.

Unknown 2
47:07 - 47:09

Thank you, guys.

Fredrik
47:09 - 47:14

Before starting the video, maybe we have a couple of questions here. Ulrich.

Ulrich Trattner
47:19 - 47:53

But that's just taking up until Q4. Thank you very much. Me again. Um. Two questions. And first of all, potentially on the FDA situation, because there is a lot going on with the Clear Labs and the lab-developed tests in the US. And obviously, you've now taken the position to clear a few tests to be FDA approved. How important is it that you struck this Illumina agreement in regard to these tests? Because MiSeq, at least as far as I'm aware, is the only FDA-approved NGS machine.

Thijs Kipling
47:54 - 48:47

And to that point, it's very binary. Without that agreement with Illumina, we couldn't pursue. Or at least it would be a very challenging route. The reason for that is Illumina has a research-use-only test, which cannot be used for a cleared FDA test, and they also have the RD, that diagnostic box which is locked. So you can't tweak it on a user level, which is going to be very important because that's where we will substantiate all the data that we are generating so that the customer more or less is left with just pressing a button, and then the customer knows that whatever is now happening within the machine has been validated in accordance with the standards and cannot be tweaked by the user. So, and that is very binary. Without those agreements with Illumina, we wouldn't be able to stand here and declare an ambition to pursue FDA clearance.

Ulrich Trattner
48:47 - 49:10

And just a follow-up question on that, I believe we discussed this during the last earnings call: cystic fibrosis is one of the tests for which you're pursuing the FDA route, and the competing product on the market today is from Illumina. And you say that it's a binary path forward, requiring alignment with Illumina. So can you just outline how this works?

Thijs Kipling
49:10 - 50:18

So they are FDA cleared to my recollection already, right? Um, Illumina is also one of the few products currently available and fulfilling the guidance that was recently issued about a year ago, where you need to monitor and match 100 markers, right. But as I've also said at that earnings call, there are not that many companies actually having products that, with or without FDA approval, actually fulfill the threshold defined by the association behind the guidelines. And going forward, you know, this is obviously a play to win in this market. Right. And overcoming that regulatory barrier will enable us to gain much broader traction within the US. Obviously head to head with Illumina, but they play a double-edged sword. They need to allow companies like ours onto their platforms. And I think from our meetings, we have had several. We know our friends at Illumina very well, also from my own past career days at Agilent. And they do want to have these types of partnerships.

Ulrich Trattner
50:20 - 50:56

And my last question might sound a little bit biased here, but how important is it that you're a European diagnostic company developing generic test kits when addressing this large hospital market? Because you're going up against lab-developed tests. These are designed to work in single labs or a chain of labs. These are not designed to fit into the workflow of a hospital. So how significantly does that contribute to you capturing a majority market share in this niche?

Thijs Kipling
50:56 - 52:03

I think within these niches and there are several. So that's the beauty and the challenge with devices, is that we need to look very specifically at each segment before we can confirm anything. Right. But I think when doing that across cystic fibrosis and across transplantation, the market should be perfectly suited to take on a test like ours. Going into oncology, I think it is a little bit different, right? Because the other dynamic is different. We work and serve an amplicon-based technology, which is much more targeted. And also, all our products are very diagnostically focused. Right? It's very binary. Yes or no. In the oncology space, there is a ton of additional data and information as you sequence a whole genome, which is not where we are playing. So I think our assays, and there are multiple different ways of getting them integrated into a workflow that is already pre-existing in a successful way, with technical terms that serve as enhancements and so forth. So I don't see that as in any way a barrier. Great. Thank you.

Unknown 2
52:04 - 52:05

Do we have time?

Fredrik
52:05 - 52:08

Yes, we do have time. And Ludwig, also after you.

Unknown 1
52:08 - 52:23

And also all our products are very diagnostically focused. I'll be quick. So you spoke a bit about the test for the other solid organs. So heart, lung, and liver. But McLoughlin did not mention them when discussing the 2025 launch. So what's the plan here?

Thijs Kipling
52:23 - 52:55

I think they are actually already in the hands of most of the companies out there in the research use fashion because essentially it's the same product you can use for these different organs. So Michael and the team are working with leading experts like you and Jonas and fellow people also in Canada and so forth, as he talked about, to validate so that, from a regulatory perspective, it can be launched as well. And I think we have declared that we are using those.

Unknown 2
52:55 - 52:57

Yeah. So they are in the IVD.

Thijs Kipling
52:57 - 52:58

So, um.

Unknown 1
52:59 - 53:00

And also all our products are very diagnostically focused. And also all our products are very diagnostically focused.

Fredrik
53:00 - 53:05

Thanks, Mike. And more showed highlights and we are behind highlights with these products.

Unknown 2
53:05 - 53:05

All right. All right.

Unknown 1
53:05 - 53:06

Okay.

Mikael Olin
53:06 - 53:08

The freedom to choose my own highlights. Okay.

Unknown 1
53:09 - 53:30

All right. Thanks. And just the last one then, um, so just thinking about the difference when you are offering the tests in your CLIA lab versus selling them to the hospitals. So from the hospital's perspective, is there a benefit that they receive some revenue stream from the test versus now when they are only sending their samples to Canada, for instance?

Thijs Kipling
53:30 - 55:17

That's a great question. Yes. I mean, that's why I'm so excited about what we are about to do here, because today there is that. How it works is, in broad terms, the patient goes to the hospital for post-transplantation follow-up, gets the blood draw, and then that sample is sent out to Natera. Any of those very successful companies out there. And then they get a result back. And there is very limited reimbursement flow to the hospital. So they get zero benefit. You can say, and I think, and I personally, subjectively believe that not only can we lower turnaround time, which matters for healthcare providers like the gentleman over there, but also in the U.S. As we all know, it's a very capitalistic market. Money really matters. And here we will open up a channel of revenue going into that hospital system. So I don't think I need to carve out much more argument to have a very meaningful conversation with the decision makers in US hospitals. So they do want. That's why they're in the profession. Make it better for the patients if they can lower turnaround time instead of being two weeks to one week or even lower. Of course, that would be a compelling argument, but when they can also present that argument to their administration and say, we're going to have to invest some money over here. But if we do that, and Jeff fulfills his promise, then there will be a very significant revenue flow that those hospitals can benefit from.

Unknown 2
55:18 - 55:18

Okay, great.

Fredrik
55:18 - 55:21

Two more short questions. One from Ludwig and one from Pontus.

Ludwig Lundgren
55:22 - 55:32

Okay. Yeah. So continuing a bit on that last one. So would you say that the transplant clinics typically have the, you know, instruments and competence already to run your tests, or?

Thijs Kipling
55:33 - 56:11

I think that is a question we're still exploring together with Thermo Fisher, mapping out who has the RUO and who has the DX instrument. So, there we are already screening and scouting that market. We are pretty well ahead because there are other instruments that those laboratories may also need in some instances for technical purposes. But a TapeStation from Agilent is validated in our workflow. Some of them didn't. We had a successful agreement with Agilent so that Thermo Fisher can place those boxes out there, and we're now doing the same with Illumina.

Ludwig Lundgren
56:12 - 56:37

So continuing a bit on that last one. Thank you. Um, and then also on the RHD test, I believe you still have quite limited sales in the US for this. Although you have the approval in the LTT setting at your lab, what is typically required for you to sell this test? Is it going out to different hospitals and, you know, selling your service, or how is the sales process typically going here?

Thijs Kipling
56:37 - 58:01

I mean, that can go many ways. I personally believe in partnerships in this one because this is going to be so broadly spread across the country. So if I were to sustain a sales force that would be successfully knocking on those doors, it would be a rather significant investment that we would have to make. There's one, to my knowledge, real big player out there who successfully has an RT test, which was quite timely. Also with the shortage of RhoGAM, which is the prophylactic injection that has been dominating the US market, there is one player. They did have an earnings call release just a few weeks ago with quite attractive growth, especially from the R&D. And then you have four or five or six other equally large companies in the US who don't have one. And I feel rather confident that they are looking at devices because these devices have a test that is already validated on US soil in our lab. So we can rather quickly get into the network, which is a payer term, and benefit from those infrastructures, though they are still to be proven. So. But I feel confident that at least we are well positioned to have that conversation.

Ludwig Lundgren
58:02 - 58:06

Right. And then it would be sold as a send-out test from the reference lab. You're right.

Thijs Kipling
58:06 - 58:17

Then it could be either sent out as a reference test from our lab, or it can be them buying our kit essentially and validating it in their own laboratory. So continuing a bit on that last one. It can be both ways. Thank you.

Unknown 2
58:24 - 59:09

Thank you. Pontus Stockman from Protein Funds. Um, well, thanks for hosting this. First of all, very informative. One risk that we're running here with all the excitement and all the new products and whatnot, and you're showing these very interesting scenarios, is there's a bit of absence of timelines, and we have a bunch of finance-literate Excel jockeys in the room. And it's very easy to get carried away in Excel trying to figure out what something is worth. But it's quite different to run a company than running an Excel spreadsheet. So could you provide us with some guidance on when we should expect these milestones and these scenarios? Is there a timeline attached to them, or how should we think about them?

Fredrik
59:09 - 59:47

Yeah, I agree with you. We have a lot of opportunities, but we are cautious about saying too much about timelines. One question we get quite often is the timeline for the FDA approval for the product in question. We would like to wait a bit until we have some more information about that, because my experience is that they are always delayed and are not provided earlier than expected. So we are a bit careful. As soon as we have more information, we will share that for the accept. Same goes with the other products. We are a bit careful for the time being.

Thijs Kipling
59:48 - 59:59

Yeah, I think one usually only goes one way, right? I mean, it's, yeah, things take more time than we and our customers want. Um, and so forth. So.

Fredrik
60:00 - 60:22

And what we have are our financial targets, and we will come back to them at the end of the day. So that's what we stick with. Thank you. Thank you. With that, I think we should move on then. We are 2 or 3 minutes late, but let's move over to Jeff Saltzman.

Jeff Saltzman
60:26 - 71:07

Thank you for your time today. I'm Jeff Saltzman, vice president of market access and public affairs at Divisor, based in the Washington, DC area of the United States. My career in market access and the diagnostics industry spans more than 30 years, having held leadership roles at various innovative companies, including at Corex, where I led the effort to secure Medicare and private payer coverage for Alicca Kidney, which became the foundation for their entire Alicca franchise. Today, I'd like to share how Divisor is strategically building our US market access presence through a sophisticated dual model approach, leveraging the work we do for testing services offered at our laboratory in Georgia to support our long-term kit objectives for years to come. My comments today pertain to our US based business. So what is market access? The term market access generally refers to three core elements: coverage, coding, and reimbursement. Coverage means that the payer community has deemed our testing to be medically necessary, and as such, they provide positive insurance coverage for our services. Coding. Meaning how we bill payers, both public and private, using CPT codes that are issued by the American Medical Association or AMA. Meaning how we bill payers, both public and private, using CPT codes that are issued by the American Medical Association, or AMA. And reimbursement assures that our services are paid at a rate that is acceptable and appropriate. As this relates to our efforts in the United States market, we are creating coverage pathways for laboratory services that could be leveraged for our future kit business, beginning with obtaining coverage with Medicare, which I'll discuss in just a moment. Second in the process, involves implementing a comprehensive coding strategy that aligns with both public and private payer requirements. Private payer requirements serve both business models. Third, we will work to secure competitive reimbursement from Medicare as well as the private payer community. I'd like to give you an example of Divisor's dual business model approach from a market access perspective. Of course, Divisor Genomic Laboratories, or GL, is our laboratory in the state of Georgia. We're pursuing Medicare coverage for our Transplant Tracer Cell-Free DNA assay to be performed as a service in Georgia in the future. We'll also be seeking Medicare coverage for the Divisor One Lambda except cell-free DNA test kit, which is the same test as Transplant Trace. Transplant Trace is the service, and Accept cell-free DNA is the kit. DNA is the kit. The work we are doing now is to establish coverage, coding, and reimbursement for transplant. Trace will be leveraged to support the accept cell-free DNA test kit, meaning that our clients who purchase these kits should have a clear pathway to getting paid for the testing that they perform. The advantages of this approach are numerous, including that it provides the Divisor with a revenue opportunity in the near term for the services that we perform in Georgia. It also provides Divisor with the opportunity to gain and grow our market presence in the United States. And of course, it gives Divisor the opportunity to build relationships with transplant centers nationwide. For this particular test, Divisor will soon be able to offer both the service and the kit to transplant centers, giving them the flexibility to choose the approach that works best for their needs. This also provides transplant centers with a potential revenue opportunity when they perform testing using our kit, as opposed to sending the test to a third party. I see this as a win-win opportunity for both transplant centers and Divisor. So let's talk about Medicare. Medicare, administered by the Centers for Medicare and Medicaid Services, or CMS, is the federal health insurance program covering more than 67 million Americans. While Medicare primarily serves seniors 65 and older, it also covers certain Americans with disabilities regardless of age, including those diagnosed with end-stage renal disease or ESRD. This automatic Medicare eligibility continues after kidney transplantation, resulting in Medicare coverage for approximately 80% of kidney transplant recipients. This creates a clear market opportunity for Divisor and Transplant Trace, where Medicare will be our primary payer once coverage is established as the nation's largest healthcare payer and primary coverage decision maker. Securing Medicare coverage is key to our success. While Medicare coverage policies can be established nationally by CMS through a national coverage determination or an NCD, most molecular diagnostic coverage decisions are handled regionally by Medicare administrative contractors, or MACs, as they're known. Georgia Laboratories, under the jurisdiction of Palmetto GBA, one of the aforementioned MACs, launched the Moldex Molecular Diagnostics program in 2011 to perform technology assessments, determine pricing, and publish coverage decisions for molecular diagnostic testing for Medicare beneficiaries located in their jurisdictions, which again includes the state of Georgia. Moldex is considered the gold standard for molecular diagnostics coverage decisions. Our strategic location in Georgia provides Divisor with significant advantages, including a clear pathway to Medicare coverage via the program, standardized technical assessments, and coverage decisions that often influence both Medicare Advantage insurance plans and commercial insurers nationwide. Our market access goals are strengthened by strategic partnerships with key industry coalitions that align with our core business objectives. Divisor has memberships in AdvaMed and C21, the Coalition for 21st Century Medicine, reflecting our commitment to both business models through AdvaMed, the largest medical technology association in the United States. We gain broad medical device expertise and direct support for reimbursement planning. This will be especially valuable to us as we prepare for kit submissions to both the FDA and CMS. Our membership in C21 gives Divisor deep insight into public and private molecular diagnostic testing policies that could impact coverage, coding, and reimbursement for our testing. Together, these memberships ensure that we stay ahead of any industry changes while building value for both our laboratory services and kit businesses. They provide practical resources and expertise that can be used right now at device or genomic laboratories, which will directly benefit our future kit customers. These relationships are particularly valuable as we navigate an evolving regulatory landscape. And speaking of the evolving landscape, I'd like to address how we're approaching regulatory developments in the United States. As some of you may know, in May of this year, the US Food and Drug Administration issued their final rule for oversight of laboratory developed tests, often referred to as LDTs, with initial compliance beginning in May of 2025. While there are pending legal challenges, potential legislative alternatives, and an upcoming administration change, our approach remains proactive yet flexible. Through our industry associations. We maintain real-time awareness while preparing for various scenarios. This ensures we are well-positioned to adapt and succeed, regardless of how the regulatory landscape evolves, and our membership in both AdvaMed and C21 gives Divisor a seat at the table, so to speak, with policy discussions and decision-makers. Further, we've recently hired a US-based Director of Quality and Regulatory Affairs to ensure we are prepared for whatever awaits us in 2025 and beyond. As I mentioned, we're now preparing for our first submission to Moldex for coverage of Transplant Trace to strengthen our submission and help ensure a successful outcome. We've engaged with two former Moldex associates, who previously were reviewers and have direct, first-hand experience with the Moldex technology assessment process. I'm happy to report that we're making great progress, and in fact, we have our first pre-submission with Moldex in December. We've applied to be a participating Medicare provider, which is a requirement to actually bill Medicare for the services that we perform. We are registered with MolDx not only for Transplant Trace, but also as a first step in obtaining coverage for our first four assays that we'll be offering from our lab in Georgia. We've developed a coding and pricing strategy for our testing, which I'll expand upon in just a moment. And finally, we have a revenue cycle management company under contract to handle our billing. Therefore, once we achieve Medicare coverage of transplant trace, we'll be well prepared for a successful launch. I'd like to talk for a moment about Divisor's value proposition with the payer community here in the United States. Payers are motivated when companies like Divisor can offer high-quality, cost-effective care that provides clear clinical utility and improves patient outcomes. In the case of Transplant Trace, our value proposition centers on delivering high-quality transplant monitoring while reducing overall costs. Tests that are similar to Transplant Trace have been historically priced close to $2,800. By positioning Transplant Trace at a lower price point than current alternatives, we're demonstrating our commitment to sustainable healthcare economics not only for payers such as Medicare, but to transplant centers and transplant patients alike. And we can do this while still maintaining excellent margins. Further, our plan includes applying for a category one CPT code with the American Medical Association post-launch, which will solidify our coding and pricing on the Medicare Clinical Laboratory Fee Schedule. It's another win-win for Divisor and transplant centers alike. So in summary, I'll close by emphasizing our path forward for market access in the United States. We anticipate our first Medicare coverage determination for Divisor or genomic laboratories by next summer. Establishing a revenue channel for the company. Through our laboratory in Georgia. Our experience there will inform our commercialization and coverage pathway. Creating a repeatable process for future market expansion with additional lab services and test kits, with both laboratory and kit offerings, we are building a practical approach to serve the US market effectively and successfully. Thank you for your time and interest today.

Fredrik
71:08 - 71:15

And we have a couple of questions from the audience here. We take them immediately. Ulrich Trattner, to start with.

Ulrich Trattner
71:16 - 71:57

Great. Can you hear me? Great. Thank you very much, and thanks for taking my questions. Um, if we start off, there's been a lot of focus, of course, on getting reimbursement here for Medicare and Medicaid. So where do you see the risk lying in that? And it seems like a lot of companies are increasingly positioning themselves to address private pay. So, just how much or how are you working on getting access to this?

Jeff Saltzman
71:59 - 72:11

Well, um, if I understand the question correctly, are you asking if the new administration coming in affects our path forward, or are you specifically asking me,

Ulrich Trattner
72:11 - 72:24

What risks do you see in the path forward in terms of reimbursement levels, as well as how you're addressing and how you're working with private pay, in addition to the Medicare and Medicaid segment?

Jeff Saltzman
72:24 - 75:04

So, you know, clearly, it's anybody's guess with what's going to happen over the next couple of months and years. What I would say, and this is my own personal opinion, is that with the Trump administration coming in, I would venture to say there's slightly less risk for a major impact on pricing with the clinical laboratory fee schedule. Um, with the FDA final rule of oversight for LDTs. Uh, you know, that's really where I thought your question was going, actually, um, because, you know, the first stage of the final rule comes into play in May of next year. As I was saying in my presentation, all of the conference calls with the industry groups that I mentioned in my presentation are all suggesting that labs like ours need to continue to move forward and be prepared for FDA oversight. But, um, there's, you know, there's a slightly lower chance that the Trump administration is going to make this a priority, or rather, that they would make it one. We think there's not a big chance that I worded that wrong. Sorry, there's that. The Trump administration will likely not make this a priority. So, which means that the final rule, you know, would stay in effect. But at the same time, um, there are, you know, uh, there are Republican members of Congress, uh, that have expressed, uh, that there should be an alternative, uh, LDT regulation as opposed to the final rule. So that's why I say, you know, where where will this all shake out? I don't know, but we just need to make sure that we're prepared for May of next year, which we are. Um, as far as pricing, that's a great question. And as I sit here and think about it, I believe that for our immediate plan, say, you know, for 2025, um, in terms of, you know, what I laid out and, uh, with the launch of Transplant Trace, the initial price is going to come from Moldex anyway, and not from CMS or through the clinical laboratory fee schedule. So I don't think that there is a big risk of being negatively impacted there. And as I also mentioned in my presentation, we plan to work with CMS and the payer community. We believe we can offer Transplant Trace at a lower price than the competitors and still do really well with it. Um, so I think if we were going in and expecting a higher price than the competition, I would be a little nervous, right? Right now. But knowing what I know in terms of, you know, what our plans are for pricing and coding, I think we'll be okay. I really do.

Ulrich Trattner
75:05 - 75:06

Okay, great.

Unknown 3
75:06 - 75:07

Um, with the, uh, with the FDA, uh, final rule of oversight of LDTs. Um, with the, uh, with the FDA, uh, final rule of oversight of LDTs. Um, with the, uh, with the FDA, uh, final rule of oversight of LDTs.

Fredrik
75:08 - 75:11

One more question before we take a short break.

Ludwig Lundgren
75:11 - 75:36

Um, with the, uh, with the FDA, uh, final rule of oversight of LDTs. Ludvig Lundgren again from Nvidia. Hi, Jeff. Um, so just a question on the pricing and reimbursement value that you mentioned there at the end. So you're planning to be a bit lower than competitors, if I understood correctly. Could it be that hospitals might choose to still go with the other options that are more reimbursed, so to speak. Or will this be more beneficial from the hospital side as well?

Jeff Saltzman
75:37 - 76:29

No. Well, it's still beneficial to the hospital side. That's a great question. But let me explain that with the send-out model to carry out, for example, transplant genomics, name your lab when it's sent out like that. The hospital really doesn't make a penny. You know, the money for the testing goes to the lab that's performing the testing. So whether that's reimbursed at, you know, the approximate $2,800 that they're currently getting or something lower that we're looking for, it's still money that they're not getting today. So, I think that most transplant centers will still find it very attractive to run the test and collect that money. You know, reimbursement usually just comes down. Right. And so here's an opportunity for a transplant center to make more money for testing that's already being performed. But they get to keep it this time. So, as I was saying, I really think that transplant centers are going to find that very attractive.

Ludwig Lundgren
76:29 - 76:36

Could it be that hospitals then choose to still go with the other options that are more reimbursed, so to say? And do you think that this will then be a very profitable product for the hospitals?

Jeff Saltzman
76:38 - 77:52

You know, I mean, I would defer to Tyce to talk about the pricing of it, but just in terms of, you know, what we will sell the test kit for or what Thermo Fisher sells the test kit for versus where I expect reimbursement to land. You know, again, as I mentioned, although I was talking about transplant trays as a service, the margins are still very, very strong. Uh, you know, the cost of NGS technology has come down a lot since DH launched in 2017, and Medicare knows that. By the way, I've actually had a conversation with the medical director at Moldex about this very topic more than a year ago, before I was with the company. Uh, so that's why I think that Medicare, knowing what I know about how, you know, Moldex views pricing for these types of tests, and where we plan to come in at, I think Medicare will be very happy. The transplant centers will be happy that, you know, eventually this will be an opportunity for them to make additional revenue. And the private payer community is always looking to save money. So, um, I think that we will be very well positioned with this.

Fredrik
77:53 - 78:40

Could it be that hospitals might choose to continue with the options that are more reimbursed? Could this be that hospitals then choose to still go with the other ones that are more reimbursed, so to say. Jeff, you will have an opportunity to ask questions to Jeff during the general Q&A session. Now it's time for a short break. We said earlier, uh, 3:00. Let's meet here. Five past, coffee is served in the lounge where you met earlier. Take an opportunity to grab one of our 20-year anniversary books on the table outside. You can also see our products outside here. So, let's meet here at three past. And then I have the pleasure to introduce Jakob Nielsen. The next speaker. And he will introduce himself. Welcome to the stage. The stage is yours. Thank you. Fredrik.

Jakob Nielsen
78:43 - 104:36

So? So this is me, right? So I'm the head of transplant immunology at the University Hospital of Zurich. And I'm also a medical advisor here at De Visser. And I've been in Zurich for the past eight years, heading transplant immunology there. And before working in Zurich, I was at the Karolinska for many years, focusing on infectious diseases, immunology, and transplant medicine. So I'm here today to talk a little bit to you about what's called donor-derived cell-free DNA in post-transplant monitoring. So what I will talk about is all about solid organ transplantation. So it's not about stem cell transplantation. So we're talking about kidney transplantation, lung transplantation, liver transplantation, and heart transplantation. Pancreas transplantation is the main focus. What we do in Zurich and what's done worldwide. And I hope that I'm not going to be too technical for you. Um, but I'm going to try to give you some background and then get into the assay a bit and then get into how we're using it at the moment and what I see a bit in the future. So just to start, a bit of background on donor-derived cell-free DNA and on cell-free DNA in general. So in the bloodstream, of course, you have a lot of cells floating around, and most of them have DNA inside of them. But you also have DNA that's not cell associated. So you have DNA that's floating around by itself without being associated with cells. And this is what we refer to as cell-free DNA. And if you look at cell-free DNA in a person, not in the transplant setting but just in a normal human being, this presents a very interesting diagnostic possibility because you can think about it. For instance, in pregnant females, we know that the fetus will secrete cell-free DNA into the circulation. We use this for a lot of prenatal diagnostics where we can look at trisomy 21, for instance. Or you can perform various other fetal diagnostics. You can have it in the setting of tumors, which aligns with the concept of a liquid biopsy, where you can see the DNA that's being secreted from the tumor cells, and you can sequence it, look at the mutations, and quantify it in a setting of tumor biology. And you can also, of course, look at the cell-free DNA just from your own body, because cell-free DNA is derived from cells that are either dying through necrosis or apoptosis. So it will be a reflection of what's happening in your body at a certain time point. So the cell free DNA will be typically in the form of quite short oligonucleotides. So the length of these oligonucleotides is typically around 150 to 200 base pairs, centered around 170. And this has to do just with how the DNA is coiled on the nucleosomes and how it's degraded by nucleases. But this will be your peak size where we find the cell free DNA. And of course, in this setting, if you have a transplanted kidney, you will have a mixture of your own cell-free DNA and cell-free DNA coming from the transplanted organ in your bloodstream as a transplant recipient. So you will have both of these cell free DNA molecules existing at the same time. And, of course, it's a given that if your transplanted kidney experiences a lot of cell death and cell loss within the graft, it's going to release a lot more cell-free DNA into the circulation as a marker of what we call graft damage. And we can, with a lot of different techniques, identify differences because there are genetic differences in the transplant graft compared to the recipient. We can, with several different techniques, decide if the cell free DNA that we are finding is coming from the organ that's been transplanted, or if it's coming from the recipient itself. So you can do this with sex mismatches, and you can use different types of polymorphisms between individuals to determine from which part of the body this DNA is coming. Is it coming from the transplanted organ or from the recipient itself? And you can also do this with different types of technology platforms. So you can use different types of next-generation sequencing, or you can also use qPCR or digital droplet PCR. And it all boils down to a basic calculation in the end, where we want to know how large a fraction of the total cell free DNA is coming from the transplanted organ. And this is what we quantify in the end with these assays. So that's just a very brief background on cell free DNA and donor-derived cell free DNA. So I just wanted to switch a bit into post-transplant monitoring, just to give you a sense of what we are doing with our transplanted patients after transplantation. And post-transplant monitoring is all about this. So it's all about trying to extend the survival of the transplanted graft, which indeed extends the survival of the transplanted patient. Right. So this is what it's all about. So this is a graph looking at kidney transplantation from Europe with what we call death-centered graft survival. That means somebody is losing their graft without dying, right? So, it's the patient who's losing their graft and will need a new transplant graft. And you can see that there are three different eras represented here. With these eras, you can see that we are improving. Transplant outcomes are improving, which is important. But you still see that if you go out ten years, you will see that maybe also in the latest era, about 20% of the patients who are being transplanted have already lost their kidney. And this is of course, something that we want to prevent, because if they lose their kidney, then they will have to be put on the waiting list again, and we will have to put in a new kidney. Right. And if you imagine transplanting somebody who is 20 or 15, then you can imagine that they will need 3 to 4, maybe, kidneys during their lifetime. Right? And since we have a scarcity of organs, it's much better if they just need one. Right. So this is the whole aim of the field. And when you see these improved outcomes, it's also very important to note that this is in the background of the field being much more challenging today than it was 20 years ago. And why is it much more challenging? It's because of this lower hand side here, where you can see what's happened with recipient age, what's happened with donor age, and what's happened with so-called expanded criteria donors. So this is all in the setting of kidney transplantation. So what we're doing now compared to ten, 15, 20 years ago, we're transplanting older patients with older donors and with organs that are much worse than what we were using before. Right. So it becomes even more difficult, and it's because of these improvements that we can do this. Right. So because the improvements are there. So we have less risk in what we're doing. The indications for transplantation are expanding. Right. And the age gap or the age limit for when we consider transplanting a lung is expanding. So ten years ago, we would never have transplanted anybody with a lung over 60. And now we're sort of, yeah, just one lung maybe, you know, it's a very, very fresh 72-year-old. Why not. Right. Why not one lung. Right. Because the life expectancy is promising and the outcomes are continuously improving. So? So you can imagine that when we start doing this more and we're really pushing the envelope on what we're using for organs, then we need to improve our monitoring even more. Right. So, it really puts an incentive on that. So, coming back to transplant loss again, why are these patients losing their grafts? So I'm talking about kidneys all the time now. But you can extrapolate this to lung transplants and to heart transplants. And to some extent, also to liver transplants. And why are these patients losing their grafts? Why are they losing their grafts? Right. So this is a central question. So this is just one study on kidney transplantation, trying to look at patients who are losing their grafts. Why are they losing their grafts? And there are a lot of details here. And you don't have to look at it at all. But just know these 64% here, which are all due to rejection. So rejection is the big cause of loss of transplant grafts. Right. So two-thirds of the patients are losing their grafts due to rejection. And of course, if you don't want to lose your graft due to rejection, it's very important to take your immunosuppressive drugs. And you can see here that about half of them that are losing their grafts are not really taking their immunosuppressive drugs as they should. Right. So we know this is a problem, but you see that half of them are really adherent. Right? So they really take their drugs as prescribed, but still, they lose their graft. So this is the process of the immune system rejecting the graft, which is the main barrier, of course, to organ transplantation between humans. I shouldn't really say current because we have self-ID now that we're using. But with previous diagnostics or the type of diagnostics that are used in the largest part of transplant centers worldwide, we are detecting problems with the graft quite late in the process of rejection. And this is due to the fact that we are focused mostly on organ function to detect rejection. So we are screening and observing how the graft organ is functioning. And when we start to see a drop off in function, then we think that something is wrong with it. And then we do additional diagnostics. But really, usually when the drop-off comes in organ function, a process started long ago and slowly led to this problem with organ function. And often you need to lose maybe 50 to 70% of your organ function for us to notice it. Because you have additional capacity. And this is also probably why it's quite difficult to treat when we notice it. So not only is it important to notice this, but it's probably very important to notice it earlier because if we can notice these changes very early, then we can sort of stop the process at that early stage where it would be theoretically and also probably really practically much easier to stop this process. So if we're thinking about the test like donor-derived cell-free DNA and the clinical utility of it, you would have this typical clinical management algorithm where we would use these genetic differences that exist between the donor organ and the recipient to detect cell-free DNA within the blood with our NGS method. And we can then follow these relative values of donor-derived cell-free DNA and look for changes in a sort of monitoring procedure. And if we have elevated values, we can proceed with additional diagnostic steps or interventions. And I will get more into the details on that in a short while. Just before I do that, I just want to say a few words on the assay that the adviser has developed and is now selling together with Thermo and One Lambda. And so this is, as you know, an NGS-based assay. So what we need for this assay is, of course, blood, which is what we're using. Then, we extract cell-free DNA. Then we have the PCR parts of the assays to create our sequencing library. Then the sequencing library is put on the NGS device. And then we have the final step of data analysis. So it's a very generic type of laboratory work which we do for a lot of other tests that we have. So we already have the platforms in the laboratory. So we just need to put, of course, the kits onto already existing hardware. For the data analysis. It's a very straightforward setup. So what we're getting out in the end is the percentage of donor-derived cell-free DNA within the software. And we get some quality markers so that we know that the test has been running accurately. And this is the important part that I would like to touch upon, which is the software. Because the diagnostics, especially in these settings, are more complex and we have many more markers. Software is becoming increasingly important for us to truly maximize the potential of these tests. And the test uses 50 indel markers. So what are indels? So indels are genetic changes between individuals in the form of insertions. Added extra base pairs or deletions, subtracted base pairs. So it's really indels that we're looking for in the test. We use 50 indels spread out across all the autosomal chromosomes. And these have been specifically designed to not be ethnicity associated, so that you can also find informative markers between siblings and such things, which is important in transplant constellations, since it's not uncommon for living donor kidney donations to happen between family members, for instance, and you still need to be able to separate the DNA in this sense. Good. So that's the assay. So back a bit to how we're using the assays at the moment. And I think this is really one of the big usages that's really making a lot of sense. And this is to use this assay instead of doing graft biopsies. So the gold standard for diagnosing rejection at the moment is really to do a graft biopsy. If this is in the setting of a kidney transplant, typically a kidney transplant is placed subcutaneously in the lower part of the abdomen. So it's very accessible with an ultrasound. And you can do biopsies like you see in the ultrasound. You see the kidney outline here, and you see exactly what angle you want to use with your needle to do your biopsy. The problem, however, is that it's associated with bleeding, of course, discomfort. And it's also, of course, intensive as you need a physician to perform it, and the patient has to come in and stay in the hospital for a couple of hours and so on and so forth. So it's something that is a bit complicated for a heart transplant. We do endovascular biopsies either arterial or venous endovascular. So we're basically going in through the veins or the arteries, depending on whether we want to go into the right-hand side or the left-hand side of the heart. And we are basically then nipping off a part of the muscle from the inside, pulling it out. So this is also something that's invasive. You have the risk of bleeding and everything. And of course, it's labor-intensive to do this. And what you then do with the biopsies currently is that you do what we're calling histology. That means the pathologists are looking at it. So this is the glomeruli from a transplanted kidney, for instance. And they're looking for signs of inflammation and rejection. What we're also doing with the biopsies is conducting genomics or omics studies on them. So in this case, we use something called the molecular microscope, where we have 58,000 probes looking at RNA expression within the biopsy. And then we use a complex principal components analysis to place our biopsies in a matrix of other biopsies to predict outcome. But as you can imagine, doing histology for a long time for pathologists or performing large arrays is expensive and very labor-intensive. Right. So there are good techniques, but together with the invasive procedure, plus what we're doing with the biopsies afterwards. It's very labor intensive. And so what we want to get out of the test, in the sense of omitting biopsies, is what we call a very, very high negative predictive value. Right. So you want to be on the safe side. So if your test is really low, you want to be able to say with a very high certainty that you don't have any problems in your organ. Right. And for cell-free DNA, this is very nice. So if you set your cutoff very low. So here's a publication from 2022 for heart transplantation, where you can say that if you set a cutoff of 0.13%, then you have a negative predictive value of 97% for rejection, which means that in 97% of the cases, you don't need to do a biopsy in this setting. So you can omit the biopsy, right? Then, of course, everybody who has a value above the cutoff will not have rejection. But at least you can narrow down your biopsies to really focus on those where you have questions. Right. So this is the use that we're putting it to. And this has been implemented in a couple of centers. I'm just showing you data now from one center from a publication from last year. So here on the right side, you see in black the number of heart biopsies that the center is doing every year. And you can see that they implemented cell-free DNA testing in 2019. And then you see how the biopsies are decreasing significantly in the years following. Right. So here in the gray area are coronary angiographies that they also do. So you can see that they remain unchanged by this policy. So it's not that they're transplanting less or they have fewer patients because they're doing the same amount of coronary angiography procedures, but it's just the biopsies that are going down. And this is then the predicted savings, depending on your model of calculating that per patient, when you don't have to do these heart biopsies. And just to give you sort of a perspective, if we transplant a heart transplant patient. We typically perform biopsies every other week in the beginning. So it's a lot of biopsies, right. And so this extrapolates into very interesting possibilities. Good. So this is in terms of trying to skip the biopsy. Right. So this is one of the focuses that we have. The other one is in what we call early detection. So, is it possible with this technique to detect problems with the transplanted graft earlier than with current techniques? And here, the answer is also yes. So you don't have to get into the weeds of this study. But it's a study called the Proactive study, which follows around 4,600 kidney transplant patients where material has been taken for cell-free DNA analysis, prospectively gathered within the study. And then we are just looking now at the subgroup of 400 patients that had a biopsy, and around 336 of them did not show any rejection in the biopsy, and the other ones did, right. And now we're sort of stepping back before the biopsy. So you see the biopsies here at time point zero. Then you have minus one month, two months, three months, four months, five months, and six months. And we are looking at the cell-free DNA values. The cell-free DNA values that are interesting for us are highlighted in blue. And you can already see that five months and four months before the biopsy was made, because they suspected rejection, there were signs of rejection in the cell-free DNA. So it's an early marker as well for rejection, which enables us to push this time window when we detect rejection to the left and intervene earlier. So it's a very encouraging, interesting finding in a large observational cohort. So this is in terms of omitting biopsies and screening for rejection. And I think another application, which is really emerging, especially during the last year, is to use this assay to evaluate therapy response. This is interesting due to the fact that we have a very rapid turnover of cell-free DNA within the blood. So it's generated by cell death. Of course, both from a graft or from your own cells, of course. And when the DNA enters the bloodstream, it's very rapidly cleared, typically through enzymes and, of course, through different processes of phagocytosis, so that the half-life is between minutes to a couple of hours, and then it's eliminated. So you have a very rapid turnaround, which means that our analysis is really a snapshot at a moment in time, and the next day it could be different. Right. So what we're testing when we're examining these fractions is essentially a snapshot in time. And if you're thinking about this, this patient that we are following now with sequential values after transplantation and we suddenly see an uptick and we say, oh maybe it's rejection. We say we do a biopsy. We confirm that it's a rejection. And now we start to treat this rejection, right. So, the next idea is then quite obvious. So we want to see if the rejection treatment is working. And typically, this has been a bit difficult to evaluate because you need to assess your rejection treatment. You need to address the problems you have in organ function. And since I told you already that you get organ function very late in a rejection response, you can also imagine that it takes quite a while to, you know, improve the organ function once you start treating. But with cell-free DNA being a very rapid and very early marker, you can do this much quicker. So just to show you that this is something that's really coming into the field, I'm just going to show you a publication from this summer. So the publication is on the treatment of rejection in kidney transplantation. And they're looking at a new antibody targeting CD38. Doesn't matter. It can be whatever. And they're evaluating how this works. So it's a randomized prospective controlled trial. So they just have 11 patients in each group. And so they have a placebo group and they have a follow-up group. So the placebo group is just getting the standard therapy without an actual placebo. And then you have a standard group and you are treating from baseline until week 24. And this is just to show you how the biopsies are progressing. So the plot staying like this with placebo means that eight out of 11 biopsies with standard therapy are still showing rejection at 24 weeks, whereas for valsartan, you can see very, very clearly for this company. You had nine patients that cleared rejection with this therapy. It seems to be a good therapy for antibody-mediated rejection in the setting of kidney transplantation. Then they stopped therapy at week 24. And you can see in the chart that quite a few of them then relapsed into their rejection. But this is not the interesting part for us. The interesting part for us is that they, of course, conducted cell-free DNA evaluations during the study. So it's becoming a key endpoint in all studies looking at interventions. And here you can see very nicely in the group that got valsartan how the cell-free values are just going down very quickly at 12 weeks, showing a very nice treatment response and aligning with the biopsy results that they had. And you can see also, once you stop treatment, you sort of lose a bit of the difference between the groups. So I think this is really moving into the treatment monitoring aspect as well. And I think all studies going forward that are looking to try interventions in solid organ transplantation will have to include a cell-free DNA component for the evaluation. So with that, I would just like to add or just like to summarize, I might add something as well in the end, but I would just like to summarize that donor-derived cell-free DNA has been really established, I think, as a reliable, robust assay for looking at graft damage in the setting of solid organ transplantation. And it's important that the assay has a very high negative predictive value, especially if you set your cutoff very low. So it has a very nice negative predictive value, which allows you to avoid doing surveillance biopsies. And then you also have this interesting possibility of detecting rejection earlier, which allows for early interventions and sequential measurements in the setting of rejections, allowing you to assess your treatment response to therapy. And I think this is a really key thing for transplant monitoring, which is accelerating outcomes. So as you saw in my graph on transplant survival for a kidney graft in Switzerland, for instance, the mean time, the mean half-life of a kidney transplant is 13.6 years. So the problem is if you want to try new immunosuppressives, for instance, you have to wait quite a long time in your placebo-controlled trial before you can see a difference in graft loss. But if you have really good biomarkers, you can potentially reduce that timeline to six months, thereby accelerating the overall development of new interventions by using just the right biomarkers for evaluation. I think in this setting, donor-derived cell-free DNA is very interesting. DNA is very interesting. Um, with that, I'd like to finish, and I'd be happy to take any questions that you might have.

Ulrich Trattner
104:41 - 105:11

The interesting part for us is that they, of course, did cell-free DNA evaluation during the study. Thank you very much. And very interesting presentation. Um, a few questions on my end and potentially going back to sort of the last few slides on your show regarding the utilization of assays, and you showed a nice graph depicting those losing the graft despite being adherent to their immunosuppressant therapy. To what degree do you believe that these can actually be treated and saved in time for them to keep their grafts?

Jakob Nielsen
105:12 - 106:44

I mean, this is very much a psychological question. So, because adherence is a difficult problem, right. Um, so I think there, you, of course, have the possibility if you can have an early marker indicating things are going bad, and you can highlight adherence in this setting. Of course, this helps, right? So I think it's a psychological thing that you can use with the patient. So I used to work a lot with HIV patients. And there you have this excellent marker which is called viral load. The interesting part for us is that they, of course, did cell-free DNA as evaluation during the study. So you can measure how much virus they are replicating. And they have to take combination therapy, just like immunosuppressants. They have to take combination antiretroviral therapy. Right. So usually they are on three drugs. And if they are not taking their drugs and they're starting to replicate, they don't usually feel it. Right. They don't feel bad. But it's taking a toll on their immune system. By having this fantastic endpoint to inform the viral load, you can plot it for them in the form of a curve, and they can see what happens when they're not taking their drug. Right? Because you have direct feedback on that, it is immensely helpful in treating such patients, as they are also taking treatment to avoid dying within ten years. Right. Which is a very abstract thing for a person to do. And I think cell-free DNA in this setting is not as good as viral load in the context of HIV treatment. But it's sort of going in that direction at least. Yeah.

Ulrich Trattner
106:44 - 107:23

So you can measure how much virus they are replicating. Thank you. And a practical question. Like cell-free DNA tests for post-transplant monitoring. It is a fairly new product. And you mentioned during the presentation that you have a fairly generic workflow and potentially a lot of interest on my end, if you can clarify how exactly you establish that workflow and protocol for setting up this entire sequencing with the DNA extraction. And if you feel that the support out there from, from white papers from Thermo Fisher and the divisor helps to guide you on how to work with these products.

Jakob Nielsen
107:24 - 108:29

Yeah, absolutely. So I think, as Mickey was talking about, transplant medicine in general moved into sequencing maybe around ten years ago in earnest. Right. So we are very interested in these HLA genes that Mickey also talked about in the setting of the HLA loss kit. So we've been sequencing HLA genes for the last ten years using NGS. So a lot of transplant labs already have the Illumina devices in their labs. They're already extracting DNA, right. So you have automated machines for that, robots for that as well. So typically, what you need to do is just use a bit of another kit for the cell-free extraction. And then you can use the same NGS products that you already have in the lab to run these tests. So, so it's of course dependent on the size of the lab and the size of the transplant center. So if you have a very small lab and a small transplant center, you might not have moved into NGS yet. Right? So this will be more of a barrier for you. But for all the larger centers, especially university centers, they have basically all equipment in place to do this with very minor tweaks. They have basically all equipment in place to do this with very minor tweaks.

Ulrich Trattner
108:30 - 108:44

And just one last question. In your view, taking a holistic approach, how many times per year would you like to monitor a patient, specifically a kidney patient, for example?

Jakob Nielsen
108:44 - 109:59

I mean, it's difficult to predict. So I would think that we are testing at the moment post-transplant for something called anti-HLA antibodies. We're testing for the immune response against the foreign HLA proteins, typically testing at one month, three months, six months, and 12 months during the first year for standard kidney transplantation. I think that would be sort of something that a lot of laboratories would probably adopt to just do that 1 to 1. But I think you have this added component of testing in the context of rejections and for evaluating treatment responses. And this is just for kidney transplantation. So I think that's where the field is really evolving because, for sure, nobody knows exactly what makes sense. And it's of course also going to be very dependent on reimbursement as it is and how much money is really available to do these tests. And what are your options and alternatives if you look into cardiac transplantation, or heart transplantation, when you're still doing biopsies every other week, it makes absolute sense to then do it every other week, right? Because you're just exchanging one method for another, which is a lot less invasive and also cheaper. And so, I think depending on the different organs, it will also be very individual.

Ulrich Trattner
109:59 - 110:09

They're already extracting DNA, right. And I guess if one were to perform health economic studies on this, you would essentially imply this, as you mentioned, would be quite frequent.

Jakob Nielsen
110:09 - 110:37

Yes, yes. I mean, it all depends on reimbursement and pricing and what you can do. But transplant medicine, especially in the early follow-up period, is very intensive in the follow-up, and there's a lot of monitoring being done, and many laboratory values are being taken. So, in the whole scope of the first year post-transplant, this is actually very, very cheap, right? It's a very small part of the whole total cost.

Ulrich Trattner
110:38 - 110:41

Great. Thank you. And thanks for an interesting presentation.

Unknown 1
110:43 - 111:02

Hi. Um, so just one moment; I have two questions. And the first one is perhaps a bit technical, but you mentioned this 97% negative predictive value. Um, so just thinking about the opposite of that. So you don't want to give excessive immunosuppressants to a patient either. So what's the true positive rate that you have with these tests?

Jakob Nielsen
111:02 - 112:08

Yeah. So you should not see it as a test for rejection. It's a test for graft damage. And in this setting, you don't have any false positives. Because if you can detect DNA coming out of the organ, you know it's releasing DNA. So you don't have any false positives. But for instance, if you have a kidney transplant and it gets a bacterial infection, it will release a lot of DNA right into your bloodstream. So it's not a rejection, but it's an infection. So you still have to treat it. So it's really a marker of graft damage. And that means that the specificity for rejection will heavily depend upon the group that you study. Right. So you can always consider sensitivity and specificity. You can adjust it as much as you want because you can select the patient groups that you are applying it to. Right. So, it will depend on the setting. But that's why really the negative predictive value is, I think, the important part because it allows you to stratify where you need to do invasive diagnostics. And I think that's how you should apply it. So if you're above the cutoff, you perform invasive diagnostics and basically determine what the problem is. Yeah.

Unknown 1
112:08 - 112:30

Great. Great. Thanks. And the other ones, just from a broader sense. Now you mentioned that we've been doing sequencing within transplant diagnostics for ten years. So, within academia and your area as a researcher, how accepted would you say that this cfDNA is as a marker? And do you get any pushback and what kind of pushback is that?

Jakob Nielsen
112:30 - 114:14

I think there are basically two kinds of pushbacks. I think it's very accepted and well-established as a marker. So I think the question within the field is a bit about how to use it correctly and in what settings, that is, does it really provide additional value? And then, I think one should not underestimate. But this especially pertains to the US market where the pricing previously in centralized lab testing has been frankly ridiculous, right. For what they provide, it has really been off-putting for a lot of people. And so I think this is something that one has to overcome with kits that are priced reasonably according to their invention and what they truly contain, and are put into the hands of the people in local laboratories. I think really this is a key step to build back this trust. But I think, otherwise, skepticism that it won't be something that gets broadly implemented is not very prevalent. I don't see that at the moment. But as with all new diagnostics that are coming into a complex field where a lot is at stake, it's going to take time. So this is always what happens. Like so. So you want it to progress quickly and you want the implementation to happen swiftly. But it always, for me, is a slow process where there has to be adoption, of course, from the clinicians. It has to be adopted by reimbursement agencies. You have to see adoptions also from the patient community. And so, it will definitely take some time to implement it. But from, purely from a principle mechanistic viewpoint, it's very hard to see why this is not a very good diagnostic tool. Right. Yeah.

Unknown 1
114:14 - 114:18

Great. Thanks. Great.

Fredrik
114:19 - 119:14

Thank you very much, Jakob. And we will have some closing remarks now, and then we will have an opportunity to ask more questions, if you have any, to Jakob, myself, Tais, or Mikael. With our innovative products, high market growth, and a well-suited commercial organization, we are happy with our heavy investments over the last two years and have partnered with some of the best commercial partners in the world. We are confident that the positive development we have seen can continue going forward. While we may face individual challenges in some quarters, we are more than confident that the positive development we have seen over the years can continue and even be enhanced in the fall of 2021. In connection with our IPO, we communicated three financial goals in which we are still very confident. The first financial goal is revenue growth. The device growth target is to achieve an annual organic growth in excess of 30%. In 2021, we reached 42%, and in 2022, we reached 35%. And in 2023, we reached 34%. We continue to be confident that we can reach our financial goal and deliver organic growth in excess of 30%. The second financial goal is to achieve a gross margin in excess of 80% by 2024-2026. We put this target in place for 2021, when we had a gross margin of about 75%. Actually, already in Q1 2022, we reached this target, and we have been over it since then. In 2022, we reached 82%, and then in 2023, 85%. 85%. So if you exclude Q2 and Q3 this year, when we have heavily invested in the move to this facility, we have been above that target since 2022. The third financial goal is to have an operating margin in excess of 20%. Since the fall of 2021, a lot of very exciting opportunities have opened up for us, and we have pursued some of them to build our future. During 2024. And they will hopefully build higher revenue growth in the future. For example, during 2024, we have taken extra costs to build up our CLIA-certified laboratory in the US. During 2024, we have also invested significantly in regulatory work to get our products approved all around the world. And as mentioned before, the move to this building has been quite costly during 2024. However, we are very confident that the investments we have made in 2024 are very well invested money. These activities and investments will all contribute to substantially increasing future revenue. Already in 2025 and 2026, we will constantly update our long-term financial plans. Our long-term financial plan continues, and we are working with an updated long-term strategy at the moment. And based on these, we continue to be very confident that we will also reach the last financial target. That is an EBIT margin in excess of 20%. Latest during 2026. However, with growth in excess of 30% and a gross margin above 80%, this is probably only the start of a very profitable journey beyond 2026. So let's stop here and move over to the last section, the Q&A section. And please feel free to ask questions to me and to the other gentleman on my right.

Ulrich Trattner
119:18 - 120:09

Rick. Thanks. I have a ton of questions and I promise I will return to Mike before asking all of them. Um, starting off, direct sales in Europe, we're now two, two and a half years deep into converting distributor sales into direct sales. Um, and we talked about this historically, that it is a 12 to 18 month run-in phase before these markets generate meaningful profits on your end. Are you able to provide us with some type of update on where we're at in terms of that process, or are you happy about the progress? Which markets are we expected to potentially turn into direct sales in the coming years and what should we expect?

Fredrik
120:10 - 120:12

Yes, maybe I'll hand over the question to Tyson.

Thijs Kipling
120:13 - 121:26

Happy to provide some color to that question. I mean, generally, we're happy, right? I've reconfirmed that at the past several earnings calls, I'm happy about the traction and also happy about the outlook in terms of what is happening in addition to what we have already shared. I mean, Virginia is standing down there and, as I lovingly say, is part of the furniture of the device. The individual responsible for the success in Italy recently took over responsibilities in Spain, a very important market, particularly for transplantation. Additionally, he is overseeing Latin America and adding two more headcounts in Spain. We are adding headcount into the U.K. As I mentioned to you during the break. We're adding headcount to Germany, and we do so because we follow this investment logic whenever there's a certain threshold of additional new revenue. That's a trigger for injecting headcount. So if I didn't have that as the proof point to the CFO, I wouldn't get the blessing to inject those headcounts. So it's a good you know, and the fact that I do get the blessing is a positive sign of the traction that we're having in the direct markets of Europe.

Ulrich Trattner
121:27 - 122:13

Latest during 2026. And the second question would relate to one of your financial targets, the profit margin of about 20%, somewhere between 2024 and 2026. And we're about to conclude 2024. And it's quite obvious that we're not at 20%. So can you give us some type of roadmap here on how to achieve the 20% margin target, like we're sitting in this new office? Obviously, that has entailed a lot of investments. You invested in a couple of other things that perhaps should be seen as one-offs, but where should we see sort of the margins coming from? Is it purely volume on sales, or how should we sort of gap the bridge to your market target?

Fredrik
122:14 - 122:54

Good question. And as I said, we are very confident that we will reach the 20% EBIT margin by the end of 2026. We have a fully invested organization at the moment, so you will not see the growth in expenses as you did in 2023 and 2024. So. So the question and the answer is probably yes to the question of whether it will be a volume with a growth of 30% plus, and a gross margin of 80% plus; not even Tyson or Michael can spend that amount of money. So I'm rather confident that we can reach that.

Ulrich Trattner
122:55 - 123:10

And just a quick follow up on that. Is there any, like you say, that you're fully invested in the organization? Are there any gaps where you feel there is a need for investments to strengthen the organization?

Fredrik
123:10 - 123:27

Now we have this rule that if we add another €1 million in sales, then we can add another person or salesperson in that area. And that will happen also during 2025 and 2026.

Unknown 3
123:27 - 123:28

Is it purely volume on sales, or how should we sort of bridge the gap to your market target?

Unknown 4
123:34 - 124:04

Record on the call. Thank you for taking my questions. Um, so the first one would be interesting to hear a bit more on the roadmap in the US. Are there any historical case studies of where a send-out test or an outsourced LTT test has been replaced by a direct hospital test? So we can look at a sort of case study of how long it took and any historical precedents in such a scenario that you're looking at in the US.

Fredrik
124:04 - 124:09

Good question. I cannot answer that. I don't know if anyone.

Thijs Kipling
124:09 - 124:16

Maybe Jeff online would be the one I would call on. You would probably have the most insights, Jeff, but I'm not sure. Even if you can answer.

Jeff Saltzman
124:17 - 124:28

Yeah, I can't think of one off the top of my head. I apologize for that. Um, let me think about it. If something comes to my mind, I will, I will chime back in. I will, I will chime back in.

Unknown 4
124:28 - 124:53

Okay, no. No worries. I guess the core of my question is how we could consider the pathway towards achieving reimbursement after successful FDA approval. Sort of the timeline following an approval. I understand that, you know, timelines are always challenging, but if there's any way we could get a sense of that sort of post-approval timeline for reimbursement.

Fredrik
124:55 - 125:06

Did you hear the question, Jeff? We do not disclose the timeline for the FDA, but how long after an FDA approval can we expect reimbursement?

Jeff Saltzman
125:06 - 125:54

Well, keep in mind, as I was mentioning during the presentation, that Transplant Trace, which we're working on now, will set the stage, so to speak, for reimbursement for the Accept Kit software, DNA kit. So I would expect, I mean, I know you're asking about a timeline, but I would expect it to be very quick because the work will have already been done. And I'll just need to demonstrate—and we will need to demonstrate—that what they already provide coverage for with transplant trace is the same as accept cell-free DNA. Um, so I it's hard for me to be specific with the timeline anyway, but I, I would say of all the tests I've worked on, this should be one of the easiest. Uh, moving from transplantation to accept because, again, the work has already been done at that point.

Unknown 4
125:55 - 126:26

No worries. So quick, quick conversion. Quick answer. Very clear. And a final question, it seems like the FAA test portfolio and maybe oncology as well is being a little bit less prioritized going forward. Should we assume that part of the business will be sort of a slower-growing business going forward as you put more focus on the post-transplantation business? Or, you know, what should we think about that molecular diagnostic part of the business in the future?

Unknown 3
126:26 - 126:27

Yeah, I'll.

Fredrik
126:27 - 126:28

Try to answer that as well.

Thijs Kipling
126:29 - 127:15

I can, I can answer that one. Uh, no, I would not expect that the fragment analysis portfolio would be slower in growth in any way. Um, it's not something we usually brag a lot about, but I think we have a fantastic opportunity with the fragment analysis portfolio because it's a legacy portfolio. The industry doesn't know that our competitors don't have the wealth or the magnitude of products like we do. Um, and I doubt that they will bring those through IVR. We are, you know, thanks to Ola and his great efforts, very well suited to get those products towards IVR. And if we do so, I think we can corner a very attractive market that, you know, at least would maintain what we are seeing today.

Fredrik
127:16 - 127:20

But you are right, we do not develop that many new products.

Unknown 4
127:20 - 127:23

That's very clear. Thank you for taking my questions.

Ludwig Lundgren
127:29 - 127:51

Right. So, Ludwig here at Nordica. Um, so regarding your partnership with One Lambda and Thermo Fisher, you seem to be very satisfied with what they have been offering to you and how they have been helping you. So can you elaborate a bit on your thoughts, using them also to distribute other tests, maybe in the US, for example, the cystic fibrosis test? Test and so on.

Thijs Kipling
127:55 - 128:26

I think it would be speculation at this point in time, but there's obviously a clear connection. There's a pretty tight correlation between cystic fibrosis, which is a lung disease, and transplantation. Need. Right. And that probably can talk to. And that means that we also have interest from. Thermo Fisher to take this on as part of the portfolio. But there's nothing that is formalized in any way. And maybe it never will. But because it's so closely connected, it would potentially make a lot of sense. A lot of sense.

Ludwig Lundgren
128:27 - 128:33

Right. And would that be through the One Lambda subsidiary or is that another part of. Thermo Fisher then that would.

Thijs Kipling
128:33 - 128:35

I think that's a Thermo Fisher question.

Ludwig Lundgren
128:35 - 128:56

Okay, okay. Right. And the second one, you recently announced that you got, uh, an approval, uh, for the device or compact in China. Is this what you have been waiting for to start selling this product more in China? Or do you also await some reimbursement decision or so on there?

Thijs Kipling
128:56 - 129:35

No, we were waiting to get this regulatory clearance, and I believe we have been waiting seven years, something like that. Um, and in the peak days, we probably had a few million that then went away when they were tightening up the regulatory, uh, aspects down there. Now we're back and would obviously assume that it will resume to where it was and hopefully then some. But what it also does is it puts us on the map with the Chinese regulatory authorities. Right. And it also shows us and our partner in China that we can actually do this successfully. So, but we will. Time will tell. It's complex.

Ludwig Lundgren
129:35 - 129:47

Market, and I suspect there are a lot of local competitors in China. Um, how likely is it that you expect this market to be quite similar to the other markets you're in?

Thijs Kipling
129:48 - 130:23

Yes and no. Um, yes and no. I mean, for full transparency, we're not going to be investing significantly into China. Um, not that we're not doing anything because we are, as you can see, from getting complex products approved. But, uh, we have a very firm, uh, view on winning in Europe, especially the large markets that we're operating in and especially across North America. Once we see that we are where we need to be, then we can divert investments to opening up markets like China. So it will be a sequential logic that we will be applying.

Ludwig Lundgren
130:25 - 130:50

And also shows us and our partner in China that we can actually do this successfully. And the final one to jack up. Um, so yeah, we didn't have time for the questions then. But maybe I can ask it now. Uh, so the device uses indels for their tests. And I believe most, if not all, competitors use SNP-based testing to distinguish between patient and donor. Would you say this is a strength for the device? Or is this not really the main issue in the testing, so to speak?

Jakob Nielsen
130:50 - 131:37

No, I think it's definitely a strength because it allows you. So the problem with using SNPs is that you have PCR and sequencing artifacts also on the Illumina platform, which we refer to as noise. And this will interfere with your ability to be quantifiable. So I think it's absolutely a strength that you use indels instead, because typically, in other settings, you have to use more markers. And if you use more markers, you require more space on the flow cells. And you can't put so many samples on the flow cells. And so it all comes down to how economically feasible it is for the lab to run the test. So fewer markers with good accuracy is, of course, better for everyone in the end, cost-wise.

Ludwig Lundgren
131:38 - 131:44

So then, does the device test scale better than, for example, the RDX test, which I believe. Yes.

Jakob Nielsen
131:44 - 132:03

Because of you. So it depends on the sequencing device you have, how many reads you can put onto the flow cells. Right. So, of course, in this setting, if you have fewer markers per patient, you can put many more tests on the same flow cell. And they have a fixed cost. So, of course, it scales better.

Ludwig Lundgren
132:03 - 132:08

Yeah. Right. And is it possible to quantify the difference between the two tests?

Jakob Nielsen
132:08 - 132:33

I mean, you can do this. But then you have to take into account sensitivity. So, of course, the more reads you have, the more sensitive you are. So it also depends on what you want to achieve for sensitivity. But you can theoretically calculate exactly how many reads you have on a given flow cell and what that's going to give you for sensitivity. So this is what we do when we plan our runs. So we plan around how many samples we can put on a certain type of hardware. Yeah.

Ludwig Lundgren
132:34 - 132:35

Yes. Thank you.

Unknown 1
132:40 - 133:00

Um, thanks. A couple for you guys. Um, so you mentioned that you have another former deal now coming in the immediate near future for the collab. So, just around the timeline a bit. And what kind of value could that be? Is it similar to the cited one, or could you provide any sort of insight on that?

Thijs Kipling
133:01 - 133:59

If I insinuated that we have a deal, then that was an overstatement because we don't. Right. Then you would have heard about it already. But we do have interest from several well-known pharma companies, which we have had, in all fairness, since we opened the door to the lab. Right. We have not yet won successfully one of those big, big ones, but they keep on coming. We are a small company. We are a new laboratory. And I think that's something everybody should and would appreciate. That warrants some questions. And I think we are now, with a year under our belt, we've created enough substance to position us to successfully take some of those opportunities. So I remain hopeful and bullish on getting some of these deals done. If it's in the very immediate or near future, I can't promise. But, um, we are hopeful.

Unknown 1
133:59 - 134:09

Yep. Right. It sounded like you said during your presentation that it was one coming in the immediate near future.

Thijs Kipling
134:09 - 134:12

Yeah, I think let's, let's see, let's see. Right.

Unknown 1
134:12 - 134:34

All right. And maybe last one, um, I don't know who is best to answer this, but for 2025 now, like which of these different areas do you see as the biggest, biggest growth opportunities? Is it the clear lab reimbursement, or is it the thermal deal and that distribution? Or is it direct presence in the US or expanding in Europe. Like what?

Thijs Kipling
134:35 - 136:50

I think in terms of, uh, you know, at least once we hit and get fully airborne in the US, it will absolutely be North America, right? Uh, staying within the silo of transplantation, the lab will generate a lot of revenue until we have the FDA clearance with us. Right. Until then, it will be standing on two legs. It will be the research use products that will generate revenue, as that's the channel Thermo is advancing with. Right. And then the lab that we're now scaling up. And as soon as Jeff, uh, as he mentioned, you know, has succeeded with his efforts in getting reimbursement, then we will certainly see that start to scale. Right. And that would be a rather, I think, aggressive scaling at that point in time, whenever that comes. Uh, so that would mean that they were in transplantation both with Thermo and our lab, which is not covered by the contract at this point in time, will both scale, and then it will be, as I believe, more of a switch thing. You turn on that engine together with Thermo Fisher following the FDA approval. But in between here today and then, you know, RHD is a fantastic product. We just want you to know, we cover the whole of Sweden. So if you just had, uh, newborns, then they were probably tested with the device. Right. We have Germany, we have Wales. We just announced we have Canada. So, we will soon most likely cover most of Canada. Right. Um, coming back on that one with confirmation. And then, you know, once we get it into the US, if we get it into the US, I believe we will, then that will be a significant revenue driver as well. So us for sure, you know, it has to be just from the sheer size of things. The reimbursement is, you know, radically different. Um, but Europe is right there, right? So Virginia is pursuing, you know, a market opportunity similar to Italy. He has taken over Torbjörn's role, who is the other VP and head of the other markets in Europe, doing the same. And both are doing a fantastic job. So, uh, and that's the beauty. Again, we have a wide portfolio, we have a strong presence in a wide number of countries, and we haven't even started to look at the APAC, Asia Pacific, where there's a ton of opportunity. So I hope that answers a bit.

Unknown 1
136:50 - 136:51

Uh, so that would mean that they were in transplantation both through with Thermo Fisher and our lab, which is not covered by the contract at this point in time, will both scale and then it will be, as I believe, more of a switch thing. Yeah.

Ulrich Trattner
136:54 - 137:23

Uh, so that would mean that they were in transplantation both with Thermo and our lab, which is not covered by the contract at this point of time, will both scale and then it will be, as I believe, more of a switch thing. So, um, uh, a few follow-up questions on my end and potentially, like you mentioned here in passing Canada, and you mentioned a sort of imminent decision to potentially cover all of Canada. And I'm guessing you're referring to the Blood Canada tender that has been talked about. Could you quantify what that would imply? You already have a tender awarded in Canada. Just put it into context in terms of whether it is bigger, larger, or smaller.

Thijs Kipling
137:24 - 137:55

It would be with a lot of caveats. So there's one region, the largest region in Canada, the Ontario region, that has not yet been declared. Who will take that, and will it be, you know, a provider utilizing device products or not, that will influence that number? I essentially would be thinking about. So I would refrain from giving you any number until I have more confidence in that number. Right. But um, but again, also there, regardless of Ontario or not, we do have a very good position there.

Unknown 5
137:56 - 137:56

Sure.

Ulrich Trattner
137:56 - 138:15

And you have three product areas, a lot of tests in sort of subdivisions of these. Do all of these get enough attention from devices, or would potentially some of these tests fit better in a different organization where you would essentially sell these under license?

Thijs Kipling
138:16 - 138:24

It's not something we have. We have not yet gone into transplantation, which is a good example. Of course, there are multiple.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…